

Title (en)

THERAPEUTIC COMBINATIONS OF (SELECTIVE) ESTROGEN RECEPTOR MODULATORS (SERM) AND GROWTH HORMONE SECRETAGOGUES (GHS) FOR TREATING MUSCULOSKELETAL FRAILTY

Title (de)

THERAPEUTISCHE KOMBINATIONEN AUS (SELEKTIVE) ESTROGEN-REZEPTOR MODULATOREN (SERM) UND WACHSTUMSHORMONSEKRETIIONSFÖRDERER (GHS) ZUR BEHANDLUNG VON MUSKELSKELETT-GEBCRECHLICHKEIT

Title (fr)

COMBINAISONS THERAPEUTIQUES DE MODULATEURS (SELECTIFS) DES RECEPTEURS DES OESTROGENES (SERM) ET DE SECRETAGOGUES D'HORMONES DE CROISSANCE (GHS) POUR TRAITER LA FRAGILITE MUSCULO-SQUELETTIQUE

Publication

EP 1085867 A1 20010328 (EN)

Application

EP 99914723 A 19990503

Priority

- IB 9900796 W 19990503
- US 8942498 P 19980616

Abstract (en)

[origin: WO9965488A1] This invention is directed to pharmaceutical combination compositions and methods comprising (-)-cis-6- phenyl-5-(4-(2-pyrrolidin-1- yl-ethoxy) -phenyl)- 5,6,7,8- tetrahydronaphthalene -2-ol or a pharmaceutically acceptable salt thereof and 2-amino-N-(1(R) -(2,4-difluoro- benzyloxymethyl) -2-oxo-2-(3- oxo-3a(R) -pyridin-2- ylmethyl)-2-(2,2,2-trifluoro-ethyl) -2,3,3a,4,6,7 -hexahydro -pyrazolo [4,3-c]pyridin -5-yl)-ethyl) -2-methyl-propionamide or a pharmaceutically acceptable salt thereof, methods of using such compositions and kits containing such compositions. The compositions are useful for treating musculoskeletal frailty, including osteoporosis, osteoporotic fracture, low bone mass, frailty and low muscle mass.

IPC 1-7

A61K 31/44

IPC 8 full level

C07D 295/08 (2006.01); **A61K 31/40** (2006.01); **A61K 31/402** (2006.01); **A61K 31/435** (2006.01); **A61K 31/437** (2006.01); **A61K 31/44** (2006.01); **A61K 31/444** (2006.01); **A61P 1/02** (2006.01); **A61P 19/00** (2006.01); **A61P 19/08** (2006.01); **A61P 19/10** (2006.01); **A61P 43/00** (2006.01); **C07D 471/04** (2006.01)

IPC 8 main group level

A61K (2006.01); **C07D** (2006.01)

CPC (source: EP KR)

A61K 31/44 (2013.01 - EP KR); **A61P 1/02** (2018.01 - EP); **A61P 19/00** (2018.01 - EP); **A61P 19/08** (2018.01 - EP); **A61P 19/10** (2018.01 - EP); **A61P 43/00** (2018.01 - EP)

C-Set (source: EP)

1. **A61K 31/44** + **A61K 31/40**
2. **A61K 31/44** + **A61K 2300/00**

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE

DOCDB simple family (publication)

WO 9965488 A1 19991223; AP 9901581 A0 19990630; AR 018868 A1 20011212; AU 3342099 A 20000105; BG 105128 A 20011130; BR 9911357 A 20010313; CA 2335112 A1 19991223; CN 1305378 A 20010725; CO 5070586 A1 20010828; EA 200001189 A1 20010625; EP 1085867 A1 20010328; GT 199900083 A 20001205; HR P20000857 A2 20011031; HU P0102395 A2 20011128; ID 26726 A 20010201; IL 139587 A0 20020210; IS 5727 A 20001124; JP 2002518328 A 20020625; KR 20010052817 A 20010625; MA 26648 A1 20041220; NO 20006381 D0 20001214; NO 20006381 L 20001214; OA 11569 A 20040701; PA 8472101 A1 20000929; PE 20000633 A1 20000726; PL 345064 A1 20011119; SK 18902000 A3 20011203; TN SN99118 A1 20051110; UY 25557 A1 20010131; ZA 993973 B 20001215

DOCDB simple family (application)

IB 9900796 W 19990503; AP 9901581 A 19990610; AR P990102847 A 19990615; AU 3342099 A 19990503; BG 10512801 A 20010108; BR 9911357 A 19990503; CA 2335112 A 19990503; CN 99807381 A 19990503; CO 99037624 A 19990616; EA 200001189 A 19990503; EP 99914723 A 19990503; GT 199900083 A 19990614; HR P20000857 A 20001214; HU P0102395 A 19990503; ID 20002604 A 19990503; IL 13958799 A 19990503; IS 5727 A 20001124; JP 2000554368 A 19990503; KR 20007014140 A 20001213; MA 25622 A 19990615; NO 20006381 A 20001214; OA 1200000346 A 19990503; PA 8472101 A 19990507; PE 00052299 A 19990611; PL 34506499 A 19990503; SK 18902000 A 19990503; TN SN99118 A 19990615; UY 25557 A 19990611; ZA 993973 A 19990615